Code of conduct

This Code of Conduct is the first step to showing dedication to upholding continuous excellence in both business and ethical terms, and showing our care and dedication to products, clients and success.

Polpharma Biologics and the University of Warsaw have signed a cooperation agreement in an important step toward building the company’s international scientific cooperation platform.

Jerzy Starak’s billions invested in Polpharma Biologics are going to soon bear fruit in the form of new biosimilar drugs

Polpharma Biologics is a fast-growing business that develops and manufactures biopharmaceuticals as new molecular entities (NMEs) or biosimilars, and also delivers biopharmaceutical CDMO services.

Boost Your Career With Us

Polpharma Biologics announces global commercialization deal for biosimilar natalizumab, a key multiple sclerosis medicine.

Process optimisation for biologics is obligatory for efficient processing and reduction of Cost of Goods (COGs). Especially in the development of biosimilar antibodies, low COGs to manufacture the antibody provides a competitive advantage compared to competing biosimilar developers.

Polpharmа Biologics Group conducts business in compliance with the highest ethical standards, adhering to its established system of values which is based on compliance, honesty, responsibility and cooperation.

Building a biologics business from the ground up provides tremendous flexibility but requires the right business strategy. Polpharma has attracted worldrecognized leaders to build and manage all key biologics funcions at its new, state-of-the-art facilities, which are located in Poland and in the Netherlands, ideally situated to serve the global markets.